AR078635A1 - Compuestos de pirrolo[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la elaboracion de un medicamento para el tratamiento de enfermedades mediadas por la quinasa de janus - Google Patents
Compuestos de pirrolo[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la elaboracion de un medicamento para el tratamiento de enfermedades mediadas por la quinasa de janusInfo
- Publication number
- AR078635A1 AR078635A1 ARP100103751A ARP100103751A AR078635A1 AR 078635 A1 AR078635 A1 AR 078635A1 AR P100103751 A ARP100103751 A AR P100103751A AR P100103751 A ARP100103751 A AR P100103751A AR 078635 A1 AR078635 A1 AR 078635A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- hydrogen
- aryl
- heterocyclyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000015617 Janus Kinases Human genes 0.000 title 1
- 108010024121 Janus Kinases Proteins 0.000 title 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 150000002431 hydrogen Chemical class 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000006621 (C3-C8) cycloalkyl-(C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 229940122245 Janus kinase inhibitor Drugs 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 1
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000005167 cycloalkylaminocarbonyl group Chemical group 0.000 abstract 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 150000004943 pyrrolo[2,3-d]pyrimidines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25203909P | 2009-10-15 | 2009-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078635A1 true AR078635A1 (es) | 2011-11-23 |
Family
ID=43413616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100103751A AR078635A1 (es) | 2009-10-15 | 2010-10-14 | Compuestos de pirrolo[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la elaboracion de un medicamento para el tratamiento de enfermedades mediadas por la quinasa de janus |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US8633206B2 (enExample) |
| EP (1) | EP2488524B1 (enExample) |
| JP (1) | JP5629324B2 (enExample) |
| KR (1) | KR20120083452A (enExample) |
| CN (1) | CN102574860A (enExample) |
| AP (1) | AP2012006192A0 (enExample) |
| AR (1) | AR078635A1 (enExample) |
| AU (1) | AU2010308028A1 (enExample) |
| CA (1) | CA2776028C (enExample) |
| CL (1) | CL2012000795A1 (enExample) |
| CO (1) | CO6531451A2 (enExample) |
| CR (1) | CR20120164A (enExample) |
| CU (1) | CU20120059A7 (enExample) |
| DO (1) | DOP2012000080A (enExample) |
| EA (1) | EA201290147A1 (enExample) |
| EC (1) | ECSP12011855A (enExample) |
| ES (1) | ES2426407T3 (enExample) |
| IL (1) | IL218802A0 (enExample) |
| IN (1) | IN2012DN02577A (enExample) |
| MA (1) | MA33670B1 (enExample) |
| MX (1) | MX2012004379A (enExample) |
| NI (1) | NI201200053A (enExample) |
| PE (1) | PE20121077A1 (enExample) |
| PH (1) | PH12012500583A1 (enExample) |
| TN (1) | TN2012000146A1 (enExample) |
| TW (1) | TWI398444B (enExample) |
| UY (1) | UY32947A (enExample) |
| WO (1) | WO2011045702A1 (enExample) |
| ZA (1) | ZA201202718B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102282155B (zh) | 2008-12-02 | 2017-06-09 | 日本波涛生命科学公司 | 磷原子修饰的核酸的合成方法 |
| ES2456515T3 (es) | 2009-03-23 | 2014-04-22 | Glenmark Pharmaceuticals S.A. | Derivados de pirimidindiona fusionados como moduladores de TRPA1 |
| WO2010109329A1 (en) | 2009-03-23 | 2010-09-30 | Glenmark Pharmaceuticals, S.A. | Furopyrimidinedione derivatives as trpa1 modulators |
| WO2011005761A1 (en) | 2009-07-06 | 2011-01-13 | Ontorii, Inc | Novel nucleic acid prodrugs and methods use thereof |
| TW201111385A (en) * | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| ES2461967T3 (es) * | 2009-12-18 | 2014-05-21 | Pfizer Inc. | Compuestos de pirrolo[2,3-d]pirimidina |
| WO2012039448A1 (ja) * | 2010-09-24 | 2012-03-29 | 株式会社キラルジェン | 不斉補助基 |
| EP2734208B1 (en) | 2011-07-19 | 2017-03-01 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| RU2632870C2 (ru) | 2011-08-12 | 2017-10-11 | Ниссан Кемикал Индастриз, Лтд. | Трициклические гетероциклические соединения и ингибиторы jak |
| CN104661664B (zh) | 2012-07-13 | 2020-07-03 | 波涛生命科学有限公司 | 手性控制 |
| AU2013288048A1 (en) | 2012-07-13 | 2015-01-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
| AU2013287630B2 (en) | 2012-07-13 | 2017-05-25 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
| HRP20180061T1 (hr) * | 2012-07-17 | 2018-02-23 | Glaxosmithkline Intellectual Property (No. 2) Limited | Indolkarbonitrili kao selektivni modulatori androgenskih receptora |
| CN103896946B (zh) * | 2012-12-28 | 2018-04-03 | 浙江导明医药科技有限公司 | 用于预防及治疗多种自身免疫疾病的新化合物 |
| EP2951590A1 (en) | 2013-02-04 | 2015-12-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for assaying jak2 activity in red blood cells and uses thereof |
| WO2014123167A1 (ja) | 2013-02-08 | 2014-08-14 | 日産化学工業株式会社 | ３環性ピロロピリジン化合物及びｊａｋ阻害剤 |
| MA38347A1 (fr) | 2013-02-22 | 2017-10-31 | Pfizer | Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak) |
| EA028123B1 (ru) * | 2013-05-02 | 2017-10-31 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ АГОНИСТОВ РЕЦЕПТОРА CB2 |
| EP3095459A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
| US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| EP3095460A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| CN113278617A (zh) | 2014-01-16 | 2021-08-20 | 波涛生命科学有限公司 | 手性设计 |
| EP2924026A1 (en) | 2014-03-28 | 2015-09-30 | Novartis Tiergesundheit AG | Aminosulfonylmethylcyclohexanes as JAK inhibitors |
| CA2944433A1 (en) | 2014-05-14 | 2015-11-19 | Nissan Chemical Industries, Ltd. | Tricyclic compound and jak inhibitor |
| JP6585158B2 (ja) | 2014-08-12 | 2019-10-02 | ファイザー・インク | ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体 |
| AU2017221193B2 (en) * | 2016-02-16 | 2019-03-14 | Zoetis Services Llc | Process for preparing 7H-pyrrolo (2, 3-d) pyrimidine compounds |
| CN107098908B (zh) * | 2016-02-23 | 2021-01-08 | 欣凯医药科技(上海)有限公司 | 一种吡咯并嘧啶类化合物的制备方法和应用 |
| WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
| US20200088732A1 (en) | 2017-04-13 | 2020-03-19 | INSERM (Institut National de la Santé et de la Recherche Mèdicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| KR102857917B1 (ko) | 2019-01-30 | 2025-09-10 | 펠리카메드 바이오테크놀로지 컴퍼니 리미티드 | Jak 억제제 및 그 제조 방법 |
| IL264854A (en) * | 2019-02-14 | 2020-08-31 | Bahat Anat | Spt5 inhibitors and methods of use thereof |
| CN114025758A (zh) * | 2019-07-01 | 2022-02-08 | 钱立刚 | P2x7r拮抗剂 |
| ES2974946T3 (es) * | 2019-08-26 | 2024-07-02 | Chemwerth Inc | Compuestos (7H-pirrolo[2,3-d]pirimidin-4-il)amino sustituidos útiles como inhibidores de JAK1 |
| JP2022549506A (ja) | 2019-09-27 | 2022-11-25 | ディスク・メディシン・インコーポレイテッド | 骨髄線維症および関連状態を処置するための方法 |
| CN115836089A (zh) | 2020-05-13 | 2023-03-21 | 迪斯克医药公司 | 用于治疗骨髓纤维化的抗血幼素（hjv）抗体 |
| CN115246833B (zh) * | 2021-04-27 | 2024-08-13 | 洛阳惠中兽药有限公司 | 一种奥拉替尼化合物及其中间体化合物的制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| EA005852B1 (ru) | 1998-06-19 | 2005-06-30 | Пфайзер Продактс Инк. | ПИРРОЛО[2,3-d]ПИРИМИДИНЫ |
| EA006227B1 (ru) | 1999-12-10 | 2005-10-27 | Пфайзер Продактс Инк. | СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА |
| DZ3359A1 (fr) * | 2000-06-26 | 2002-01-03 | Pfizer Prod Inc | DÉRIVÉS DE PYRROLO [2,3-d] PYRIMIDINE UTILES COMME AGENTS IMMUNOSUPPRESSEURS |
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| PL377791A1 (pl) | 2002-11-21 | 2006-02-20 | Pfizer Products Inc. | Pochodne 3-aminopiperydyny i sposoby ich wytwarzania |
| AU2004268621C1 (en) * | 2003-08-29 | 2011-08-18 | Exelixis, Inc. | c-Kit modulators and methods of use |
| MXPA06005578A (es) | 2003-11-17 | 2006-08-11 | Pfizer Prod Inc | Compuestos de pirrolopirimidina utiles en el tratamiento del cancer. |
| US20070270588A1 (en) | 2004-03-05 | 2007-11-22 | Taisho Pharmaceutical Co., Ltd. | Pyrrolopyrimidine Derivatives |
| AU2005270068B2 (en) * | 2004-07-02 | 2012-04-19 | Exelixis, Inc. | C-Met modulators and method of use |
| AR054416A1 (es) * | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| ES2651349T3 (es) | 2005-06-08 | 2018-01-25 | Rigel Pharmaceuticals, Inc. | Composiciones y métodos para la inhibición de la ruta JAK |
| CN102127078A (zh) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| EP1913000B1 (en) | 2005-07-29 | 2012-01-11 | Pfizer Products Inc. | Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis |
| AU2006297351A1 (en) | 2005-09-30 | 2007-04-12 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
| MX391408B (es) | 2005-11-01 | 2025-03-21 | Impact Biomedicines Inc | Inhibidores de biaril meta-pirimidina de cinasas. |
| ES2622493T3 (es) | 2006-02-24 | 2017-07-06 | Rigel Pharmaceuticals, Inc. | Composiciones y métodos para la inhibición de la ruta de JAK |
| KR20080114711A (ko) * | 2006-03-02 | 2008-12-31 | 아스텔라스세이야쿠 가부시키가이샤 | 17β ＨＳＤ 타입 5 저해제 |
| WO2009049028A1 (en) | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
| WO2009115084A2 (de) | 2008-03-20 | 2009-09-24 | Schebo Biotech Ag | Neue pyrrolopyrimidin-derivate und deren verwendungen |
| PT2384326E (pt) * | 2008-08-20 | 2014-06-09 | Zoetis Llc | Compostos de pirrolo[2,3-d]pirimidina |
-
2010
- 2010-10-01 JP JP2012533715A patent/JP5629324B2/ja not_active Expired - Fee Related
- 2010-10-01 AU AU2010308028A patent/AU2010308028A1/en not_active Abandoned
- 2010-10-01 CA CA2776028A patent/CA2776028C/en not_active Expired - Fee Related
- 2010-10-01 KR KR1020127012417A patent/KR20120083452A/ko not_active Ceased
- 2010-10-01 CN CN2010800461239A patent/CN102574860A/zh active Pending
- 2010-10-01 WO PCT/IB2010/054447 patent/WO2011045702A1/en not_active Ceased
- 2010-10-01 AP AP2012006192A patent/AP2012006192A0/xx unknown
- 2010-10-01 PH PH1/2012/500583A patent/PH12012500583A1/en unknown
- 2010-10-01 MX MX2012004379A patent/MX2012004379A/es unknown
- 2010-10-01 ES ES10771200T patent/ES2426407T3/es active Active
- 2010-10-01 EP EP10771200.2A patent/EP2488524B1/en active Active
- 2010-10-01 PE PE2012000447A patent/PE20121077A1/es not_active Application Discontinuation
- 2010-10-01 IN IN2577DEN2012 patent/IN2012DN02577A/en unknown
- 2010-10-01 EA EA201290147A patent/EA201290147A1/ru unknown
- 2010-10-12 TW TW099134779A patent/TWI398444B/zh not_active IP Right Cessation
- 2010-10-13 US US12/903,554 patent/US8633206B2/en active Active
- 2010-10-14 AR ARP100103751A patent/AR078635A1/es not_active Application Discontinuation
- 2010-10-15 UY UY0001032947A patent/UY32947A/es not_active Application Discontinuation
-
2012
- 2012-03-22 IL IL218802A patent/IL218802A0/en unknown
- 2012-03-23 DO DO2012000080A patent/DOP2012000080A/es unknown
- 2012-03-29 TN TNP2012000146A patent/TN2012000146A1/fr unknown
- 2012-03-30 CL CL2012000795A patent/CL2012000795A1/es unknown
- 2012-03-30 CR CR20120164A patent/CR20120164A/es unknown
- 2012-04-09 NI NI201200053A patent/NI201200053A/es unknown
- 2012-04-13 MA MA34774A patent/MA33670B1/fr unknown
- 2012-04-13 CU CU20120059A patent/CU20120059A7/es unknown
- 2012-04-13 ZA ZA2012/02718A patent/ZA201202718B/en unknown
- 2012-04-18 CO CO12064126A patent/CO6531451A2/es not_active Application Discontinuation
- 2012-04-27 EC ECSP12011855 patent/ECSP12011855A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078635A1 (es) | Compuestos de pirrolo[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la elaboracion de un medicamento para el tratamiento de enfermedades mediadas por la quinasa de janus | |
| PE20181045A1 (es) | Compuestos utiles como inmunomoduladores | |
| EA201001619A1 (ru) | Ингибиторы протеинкиназ | |
| AR079231A1 (es) | Derivados de imidazoquinolina | |
| MA37712A2 (fr) | Inhibiteurs macrocycliques de virus flaviviridae | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| EA201001508A1 (ru) | Мостиковые гетероциклические соединения в качестве ингибиторов интегразы вич | |
| EA201492204A1 (ru) | Нуклеозиды на основе урацила и спирооксетана | |
| AR066502A1 (es) | Compuestos amino- heterociclicos | |
| EA201190235A1 (ru) | Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750 | |
| MX2010005292A (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana. | |
| BR112013007696A2 (pt) | composto, composição farmacêutica, usos do referido composto e da referida composição | |
| ECSP10010294A (es) | Derivados de pirimidina para el tratamiento de asma, epoc, rinitis alérgica, conjuntivitis alérgica, dermatitis atópica, cancer, hepatitis b, hepatitis c, vih, vph, infecciones bacterianas y dermatosis | |
| EA201001126A1 (ru) | Пирролопиримидины и пирролопиридины | |
| EA201001683A1 (ru) | Производные фенил- или пиридинилзамещенных индазолов | |
| JP2016540742A5 (enExample) | ||
| CO6290682A2 (es) | Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c. | |
| NZ703064A (en) | Inhibitors of hepatitis c virus | |
| CL2011002830A1 (es) | Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c. | |
| CY1117909T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει ολμεσαρτανη μεδοξομιλη και ροσουβαστατινη ή το αλας της | |
| EA201591328A1 (ru) | Замещенные гетероциклом тетрациклические соединения и способы их применения для лечения вирусных заболеваний | |
| EA201390163A1 (ru) | Гетеробициклические производные в качетстве ингибиторов hcv | |
| EA201692260A1 (ru) | Соединения 1,3,4-тиадиазола и их применение в лечении рака | |
| SA518390920B1 (ar) | مركبات فينوكسي أسيتاميد معالجة بإضافة حلقة | |
| EA201490213A1 (ru) | Бензофурановые соединения для лечения инфекций вирусом гепатита с |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |